Is OGI a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on British American Tobacco partnership, with net revenue (q3 fy2026, quarter ended june 30) at ~C$105.8 million, up ~49% year over year (figures in Canadian dollars). The bear case rests on the overarching risk is that cannabis remains federally illegal in the United States, which locks Organigram out of the largest potential market, limits access to US banking and exchanges for the plant-touching business, and caps the sector's valuations. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The overarching risk is that cannabis remains federally illegal in the United States, which locks Organigram out of the largest potential market, limits access to US banking and exchanges for the plant-touching business, and caps the sector's valuations. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

British American Tobacco partnership. BAT's roughly C$124.6 million of investment and its near-30% stake give Organigram a well-capitalized strategic backer, a cash cushion, and a partner with global distribution and next-generation-products expertise.

The overarching risk is that cannabis remains federally illegal in the United States, which locks Organigram out of the largest potential market, limits access to US banking and exchanges for the plant-touching business, and caps the sector's valuations. The Canadian and global cannabis industry is oversupplied and intensely price-competitive, so pricing pressure and heavy excise taxes squeeze margins even as volumes grow. Profitability has been inconsistent, and reported earnings can be distorted by non-cash fair-value changes on biological assets and investments. The large BAT stake concentrates ownership and influence, and future financings or share issuance could dilute existing holders, a live concern with cash of about C$11.7 million at June 30, 2026 and the shares below $1.00 on the Nasdaq. Regulatory change, international-market execution, and the early, unproven economics of the THC-beverage push all add uncertainty, and cannabis stocks as a group tend to be volatile and sentiment-driven.

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (British American Tobacco partnership) stalling in the reported numbers rather than in the narrative, the risk above (the overarching risk is that cannabis remains federally illegal in the United States, which locks Organigram out of the largest potential market, limits access to US banking and exchanges for the plant-touching business, and caps the sector's valuations) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is that Organigram is Canada's top cannabis producer by share, is growing revenue fast through the Motif acquisition and international expansion, and is backed by British American Tobacco, and posted record revenue and adjusted EBITDA in the June 2026 quarter. The bear case is that cannabis is federally illegal in the US (capping the biggest market), the industry is oversupplied and price-competitive, profits have been inconsistent, cash was only about C$11.7 million at June 30, 2026, the stock trades below $1, and the sector is volatile and sentiment-driven. Weigh both against your own portfolio.

Organigram Global is a Canadian licensed cannabis producer that grows, processes, and sells adult-use and medical cannabis, including dried flower, pre-rolls, vapes, and edibles, plus a growing lineup of cannabis and hemp-derived beverages. It sells across Canadian provinces, exports to international medical markets, and, through the Collective Project acquisition, sells hemp-derived THC beverages in parts of the US. It reports its financials in Canadian dollars. Since April 2026 it also owns Germany's Sanity Group, which sells medical cannabis in Germany and other European markets.

British American Tobacco (BAT) has invested roughly C$124.6 million in Organigram across three tranches through early 2025. As of April 2026, BAT held about 42.2 million common shares, around 29.9% of the company, plus a large block of preferred shares. The investment gives Organigram cash and a strategic partner with global reach, while making BAT its most influential shareholder.